Renaissance Capital logo

Clementia Pharmaceuticals Priced, Nasdaq: CMTA

Clinical-stage biotech focused on treating ultra-rare bone diseases.

Industry: Health Care

First Day Return: +9.0%

Industry: Health Care

We are a clinical stage biopharmaceutical company that is developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Our lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has shown potent activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. We are developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO) and have one Phase 3 trial and one Phase 2/3 trial, for two separate indications, planned to commence in 2017 with data read-outs planned in 2019 and 2020. We believe that if approved in FOP or MO, palovarotene could become the standard of care in either or both of these indications.
more less
IPO Data
IPO File Date 06/30/2017
Offer Price $15.00
Price Range $13.00 - $15.00
Offer Shares (mm) 8.0
Deal Size ($mm) $120
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/01/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $120
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Montreal, Canada
Founded 2010
Employees at IPO 24
Website www.clementiapharma.com

Clementia Pharmaceuticals (CMTA) Performance